midazolam has been researched along with Hypertriglyceridemia in 2 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The new propofol 2% preparation is an effective sedative agent and is safe because of the low frequency of associated hypertriglyceridemia." | 5.09 | Pharmacoeconomic assessment of propofol 2% used for prolonged sedation. ( Barrientos-Vega, R; Castellano-Hernández, M; Cuena-Boy, R; Morales-Garcia, C; Sánchez-Soria, MM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrientos-Vega, R | 2 |
| Mar Sánchez-Soria, M | 1 |
| Morales-García, C | 2 |
| Robas-Gómez, A | 1 |
| Cuena-Boy, R | 2 |
| Ayensa-Rincon, A | 1 |
| Sánchez-Soria, MM | 1 |
| Castellano-Hernández, M | 1 |
2 trials available for midazolam and Hypertriglyceridemia
| Article | Year |
|---|---|
Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs.
Topics: Adult; Aged; Critical Care; Critical Illness; Drug Costs; Female; Hospitals, Community; Humans; Hype | 1997 |
Pharmacoeconomic assessment of propofol 2% used for prolonged sedation.
Topics: Aged; Chemistry, Pharmaceutical; Cohort Studies; Conscious Sedation; Cost-Benefit Analysis; Drug Cos | 2001 |